Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle® in the US

Liege, Belgium, 24 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the New Drug Application (NDA) for Estelle® has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 23 June 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the following information, following the issuance of 3,421,052 new shares on 23 June 2020 for an amount of EUR 65.0 million in gross proceeds in the framework of the private placement via an accelerated bookbuild offering publicly announced on 18 June 2020.

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans

Liege, Belgium, 19 June 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Wednesday July 22 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium).

The agenda of this Meeting will mainly consider the issuance of two warrant plans subject to the shareholder’s approval : (i) one for the benefit of LDA Capital Ltd whereby a maximum of 690,000 warrants would be issued within the framework of the transaction announced on the 24th April 2020[1], and (ii) another for the benefit of reference shareholders (“Share Lending Warrants”) as further detailed in the supporting documentation for a maximum of 300,000 warrants.

The special reports of the board of directors and of the statutory auditor established pursuant to provisions 7:180, 7: 191 and 7:193 of the Belgian Companies and Associations Code, the notice for the EGM for the shareholders, including all details on how to participate to this Meeting and the supporting documents are available on the Company website.

[1] Press release Mithra, 24/04/2020

Mithra Successfully Raises EUR 65 Million By Means of a Private Placement via an Accelerated Bookbuild Offering

Liège, Belgium, 18 June 2020 20:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today that it successfully raised an amount of EUR 65.0 million in gross proceeds by means of a private placement via an accelerated bookbuild offering of 3,421,052 new shares (being approximately 8.74% of the Company’s outstanding shares) at an issue price of EUR 19.00 per share (the “Private Placement“).

François Fornieri, CEO Mithra Women’s Health, commented: We are very pleased to have completed this transaction with an oversubscribed book of Tier 1 and specialist healthcare investors, and a competitive pricing. This private placement represents a key step in our funding strategy, carrying us through to commercialization of for our next-generation contraceptive Estelle®, as well as the further development of Donesta®, our novel product candidate for menopause.

Mithra Launches Capital Increase By Means of a Private Placement via an Accelerated Bookbuild Offering and Provides an Update on its Financing Strategy

  • Launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering
  • Loan of EUR 20 million secured, in addition to the recent capital commitment agreement with LDA for up to EUR 50 million
  • Last building blocks in the Company’s financing strategy in becoming a commercial company

Liège, Belgium, 18 June 2020, 14:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today the launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering (the “Private Placement”).

Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

  • Mithra grants license to Spirig Healthcare (Stada Group) for commercialization of its hormone treatment Tibelia® in Liechtenstein and Switzerland
  • Tibelia® is currently marketed in about 30 countries through existing license and supply agreements

Liege, Belgium, 11 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has entered into a license and supply agreement with Spirig Healthcare AG for the commercialization of its tibolone-based product Tibelia® in Liechtenstein and Switzerland.

Mithra Issues First Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 05 June 2020 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that following the signature of the capital commitment agreement with LDA Capital Limited announced on April 24, 2020, the Board of Directors approved on May 22, 2020 an increase to the Company’s capital by means of an issuance of new ordinary shares through authorized capital. The first put option notice was issued last Friday, May 29, 2020, according to the terms of the capital commitment agreement.